Literature DB >> 16438977

Interleukin-18 levels are not associated with subclinical carotid atherosclerosis in a community population. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS).

Caroline M L Chapman1, Brendan M McQuillan, John P Beilby, Peter L Thompson, Joseph Hung.   

Abstract

Interleukin (IL)-18 is a novel proinflammatory cytokine that plays a central role in innate and acquired immunity, making it a likely inflammatory candidate in atherosclerosis. We investigated whether circulating IL-18 levels were associated with subclinical atherosclerosis in a community population. Carotid intimal medial thickness (IMT) and carotid plaques were assessed in a cross-sectional study of 1111 randomly selected community subjects, aged 27-77 years. Baseline levels of IL-18, IL-6, high sensitive CRP (hsCRP), fibrinogen and white cell counts were measured along with conventional cardiovascular risk factors. Men had higher mean IL-18 levels than women (P<0.0001). Spearman rank correlations (r(s)) showed that IL-18 was weakly correlated with all inflammatory markers in the whole population (r(s) between 0.11 and 0.23, all P<0.001). IL-18 was also correlated with conventional risk factors including waist-hip ratio, BMI, blood pressure, triglycerides, HDL (inversely) and pack-years smoking (r(s) between 0.18 and 0.39, all P<0.001) but not with LDL-cholesterol. Independent predictors of IL-18 concentrations were waist-hip ratio, HDL, IL-6, hsCRP and hypertension. There was a positive univariate association of IL-18 levels with carotid IMT (P<0.001) and plaque prevalence (P<0.001) but no residual association after adjustment for conventional risk factors (both P>0.05). In a cross-sectional community population, IL-18 levels were related to traditional risk factors and inflammatory markers but were not independently associated with subclinical carotid atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16438977     DOI: 10.1016/j.atherosclerosis.2005.12.026

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

Review 1.  The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease.

Authors:  Simon W Rabkin
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

Review 2.  The role of interleukin-18 in the metabolic syndrome.

Authors:  Marius Trøseid; Ingebjørg Seljeflot; Harald Arnesen
Journal:  Cardiovasc Diabetol       Date:  2010-03-23       Impact factor: 9.951

Review 3.  IL-18 in inflammatory and autoimmune disease.

Authors:  Saikiran K Sedimbi; Thomas Hägglöf; Mikael C I Karlsson
Journal:  Cell Mol Life Sci       Date:  2013-07-27       Impact factor: 9.261

4.  Circulating interleukin-18: A specific biomarker for atherosclerosis-prone patients with metabolic syndrome.

Authors:  Minako Yamaoka-Tojo; Taiki Tojo; Kazuki Wakaume; Ryo Kameda; Shinji Nemoto; Naonobu Takahira; Takashi Masuda; Tohru Izumi
Journal:  Nutr Metab (Lond)       Date:  2011-01-20       Impact factor: 4.169

Review 5.  Interleukin-18: Biological properties and role in disease pathogenesis.

Authors:  Gilles Kaplanski
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.